Void Research GLP-3 RT Promo-Code and COA Detailed Guide: Get Up to 30% Off with BOOST30

Void Research’s GLP-3 RT is a research-use-only material positioned around a triple-receptor research pathway, while GLP-2 TZ and CAGRI represent different experimental target classes that should not be treated as interchangeable simply because they appear in the same metabolic-research catalog. For laboratories and procurement readers, the most useful way to compare these materials is to separate molecular identity, receptor-target context, lot documentation, analytical testing, and commercial terms.

Affiliate disclosure: This post contains an affiliate link; the publisher may earn a commission from qualifying purchases.

Research-use-only notice: The materials discussed here are intended for controlled in-vitro or laboratory research by qualified researchers. They are not for human or veterinary use, consumption, administration, diagnosis, treatment, cure, prevention, clinical application, supplements, cosmetics, or personal experimentation. Nothing in this guide provides dosing, reconstitution, injection, treatment, or personal-use instructions.

For qualified laboratory procurement, the current Void Research promotional code is BOOST30, associated with up to 30% off. The Void Research BOOST30 research catalog can be accessed through https://voidresearch.shop/?ref=BOOST30.

The discount is only one part of a responsible procurement decision. A much more important question is whether the exact material, lot, certificate, analytical method, reported result, and research objective can be connected to one another without relying on marketing shorthand.

What GLP-3 RT, GLP-2 TZ, and CAGRI mean in this catalog

Void Research uses abbreviated product names for several research compounds. Independent catalog analysis has mapped GLP-3 RT to retatrutide, GLP-2 TZ to tirzepatide, and CAGRI to cagrilintide.

Those mappings matter because the three compounds represent substantially different research concepts.

Retatrutide is described in the scientific literature as a triple agonist involving the glucose-dependent insulinotropic polypeptide receptor, glucagon-like peptide-1 receptor, and glucagon receptor. A 2025 description of the TRIUMPH clinical-development program likewise identifies retatrutide as a synthetic triple agonist acting on GIP, GLP-1, and glucagon receptors.

Tirzepatide is instead characterized as a dual GIP/GLP-1 receptor agonist. Published clinical literature describes it as a dual agonist rather than a triple-receptor compound.

Cagrilintide belongs to a different mechanistic family. It is a long-acting amylin analogue with activity at amylin and calcitonin-family receptors. Structural research published in 2025 examined how cagrilintide interacts with active amylin receptors and the calcitonin receptor.

That means a catalog comparison should not reduce these products to a simplistic question such as which one is “stronger.” The scientifically meaningful comparison is what receptor system or molecular pathway is being investigated, what model is being used, what outcome is being measured, and whether the experimental design is capable of isolating that mechanism.

Why the “GLP-3” label needs context

The phrase GLP-3 RT is a commercial catalog label rather than the formal scientific name normally used in peer-reviewed literature. Researchers reviewing publications should search for retatrutide rather than expecting papers to use the retailer’s abbreviated product label.

The distinction is important for source verification.

When a laboratory searches PubMed, trial registries, conference abstracts, or scientific reviews, retatrutide is the relevant scientific entity. The “GLP-3 RT” label may be useful for navigating a supplier catalog, but it should not replace the compound’s scientific identity in a research protocol, evidence review, literature search, internal procurement record, or data interpretation.

The same principle applies to GLP-2 TZ. Scientific literature uses tirzepatide. CAGRI is a shortened commercial form of cagrilintide.

Keeping catalog labels and scientific identities separate helps prevent errors when researchers compare supplier documentation with published evidence.

Retatrutide as a triple-receptor research concept

Retatrutide has attracted significant scientific attention because a single synthetic molecule is designed to engage three metabolic receptor systems: GIP, GLP-1, and glucagon receptors. Scientific reviews describe this as triple agonism.

The research significance of that architecture is not that “three is automatically better than two.” It is that multi-receptor activity creates a more complicated pharmacological system.

In a basic receptor experiment, a researcher may investigate one receptor, one ligand, and one measurable response. A triple agonist introduces several possibilities at once. Differences in receptor expression, binding, signaling efficiency, cellular background, assay timing, and downstream readouts can influence what is observed.

For that reason, triple-agonist studies require careful interpretation.

An observed response cannot automatically be attributed to one receptor unless the experimental design isolates that receptor or otherwise separates the pathways. Suitable controls, receptor-selective comparison compounds, engineered cell systems, knockout models, antagonists, or pathway-specific assays may be needed depending on the research question.

The compound should therefore be understood as a research tool connected to a multi-receptor hypothesis rather than merely as another product in a peptide catalog.

Tirzepatide and the dual-agonist comparison

Tirzepatide provides a useful comparison because its scientific identity is centered on dual GIP and GLP-1 receptor agonism.

That creates an obvious conceptual contrast with retatrutide. Retatrutide adds glucagon-receptor activity to a signaling architecture that already involves GIP and GLP-1 pathways.

However, researchers should be cautious when comparing literature across compounds. Differences in molecular structure, receptor potency, assay conditions, exposure, species, study population, tissue environment, and research endpoints mean that results cannot be attributed solely to “dual” versus “triple” classification.

A good comparison should therefore distinguish at least four levels.

First is receptor architecture: which receptors the molecule is intended to engage.

Second is molecular pharmacology: how strongly and in what manner it interacts with those receptors.

Third is experimental evidence: what has actually been observed in the particular in-vitro, animal, or human research being cited.

Fourth is interpretation: what conclusions are justified by that evidence and what remains uncertain.

These distinctions are especially important when supplier names such as GLP-2 TZ and GLP-3 RT make products look more closely related than their full pharmacology may suggest.

CAGRI belongs to an amylin-centered research pathway

Cagrilintide should not be placed in the same mechanistic bucket as the GIP/GLP-1/glucagon agonists.

Published research describes cagrilintide as a long-acting amylin analogue. Research has examined its interaction with amylin receptors and the calcitonin receptor, as well as the structural basis of those interactions.

A 2025 preclinical study described cagrilintide as an amylin and calcitonin receptor agonist and used related experimental compounds to investigate mechanisms in animal models.

This creates a different type of comparison.

A laboratory comparing GLP-3 RT, GLP-2 TZ, and CAGRI is not simply comparing three versions of one receptor class. It is potentially comparing triple incretin/glucagon agonism, dual incretin agonism, and amylin/calcitonin-family receptor biology.

That can be scientifically useful, but only if the experiment is structured around a clear research question.

A practical research-target comparison

For documentation and study-planning purposes, the three catalog labels can be summarized as follows.

Catalog label	Scientific identity used in literature	Main research-target concept
GLP-3 RT	Retatrutide	GIP + GLP-1 + glucagon receptor triple agonism
GLP-2 TZ	Tirzepatide	GIP + GLP-1 receptor dual agonism
CAGRI	Cagrilintide	Amylin/calcitonin-family receptor agonism

This table is an identity and pathway comparison. It is not a recommendation for administration or personal use.

The real value of this classification is that it tells a laboratory where to begin its literature review.

A researcher interested in GLP-3 RT should search retatrutide and triple agonism.

A researcher interested in GLP-2 TZ should search tirzepatide and GIP/GLP-1 dual agonism.

A researcher interested in CAGRI should search cagrilintide, amylin receptors, calcitonin-family receptors, and related mechanisms.

Why evidence type matters

One of the easiest mistakes in peptide-related research writing is to combine evidence from fundamentally different experimental contexts.

An in-vitro receptor assay is not equivalent to an animal study.

An animal study is not equivalent to a human clinical trial.

A mechanistic structural study is not equivalent to a clinical outcome study.

An observational report is not equivalent to a randomized controlled trial.

A supplier COA is not a pharmacology study at all.

These documents answer different questions.

A receptor-binding or signaling experiment may help establish how a molecule interacts with a target.

A structural study may help explain receptor engagement at the molecular level.

An animal study may investigate biological responses within an integrated organism.

A human clinical study evaluates outcomes under a defined protocol in people.

A supplier COA is primarily an analytical or quality-documentation record for a tested sample or lot.

Confusing those categories leads to exaggerated claims.

The correct interpretation of a COA, for example, is not “this proves the compound works.” A COA may provide evidence about identity, purity, content, sterility, endotoxin, heavy metals, or other analytical fields depending on what was actually tested. It does not prove a clinical benefit, biological outcome, or suitability for human use.

What the current Void Research GLP-3 RT documentation shows

The current Void Research GLP-3 RT product page displays lot-specific analytical information for multiple product strengths. The page identifies current certificates, lot numbers, reported HPLC purity, measured content for some certificates, testing dates, methods, outcomes, and laboratory names.

One current entry displayed by the site reports eight assays associated with ILS Laboratories and lists fields such as purity, identity, sterility, endotoxin, heavy metals, and a fentanyl screen. Another displayed GLP-3 RT certificate is associated with Freedom Diagnostics and reports a smaller assay set.

This is useful because it demonstrates why researchers should evaluate the exact certificate rather than relying on a generic statement such as “third-party tested.”

The analytical scope can differ from certificate to certificate.

A four-assay certificate and an eight-assay certificate are not identical simply because both are called COAs.

The laboratory may differ.

The lot may differ.

The product strength may differ.

The testing date may differ.

The analytical methods may differ.

The measured fields may differ.

The results may differ.

Procurement review should therefore be lot-specific.

How to read a peptide COA correctly

A useful COA review begins with identity, not with the largest percentage printed on the page.

Researchers should first determine which product the certificate describes.

Then identify the lot or batch number.

Then compare that lot with the material being procured.

Next, note the laboratory that issued the report.

Then examine the test methods and results.

Only after those steps should the reported purity or other headline result be interpreted.

This workflow prevents one of the most common mistakes in supplier evaluation: finding a favorable certificate somewhere on a website and assuming it automatically applies to the product currently being purchased.

A certificate is strongest when the chain between product, lot, laboratory, test, and result is clear.

Purity and identity are not the same measurement

HPLC purity is one of the most frequently highlighted fields in research-peptide marketing, but purity and identity are different questions.

Purity asks how much of the analyzed chromatographic material corresponds to the target peak relative to detected impurities under the method being used.

Identity asks whether the analyzed substance is actually the intended compound.

A very high purity number without adequate identity information does not answer every analytical question.

Likewise, an identity result does not automatically establish content, sterility, endotoxin level, heavy-metal status, or every other property a laboratory may care about.

This is why the stronger approach is to read the complete analytical panel.

Your previously published COA material already addresses this distinction in depth, including HPLC purity, identity, and broader testing fields. The URL inventory includes a dedicated September 1 article comparing HPLC purity, identity, and net-content concepts, as well as LinkedIn and Substack COA guides.

Researchers who want additional background can consult the earlier Void Research HPLC-purity-versus-identity guide from that publishing series rather than treating one purity percentage as a complete quality assessment.

Why measured content matters

Another important COA field is measured content.

A vial may have a labeled nominal amount, while an analytical report may report an independently measured amount for the tested sample.

Those numbers answer a different question from chromatographic purity.

A sample could theoretically have high chromatographic purity while still containing a measured amount that differs from its nominal label.

Therefore, “99%+ purity” and “correct amount in the vial” should never be treated as synonyms.

For quantitative research, content can be particularly important because the nominal label may be used in planning concentrations, sample allocation, or analytical work. A discrepancy between label claim and measured content can affect experimental calculations.

The certificate should therefore be read as a collection of distinct measurements rather than one quality score.

Sterility, endotoxin, heavy metals, and screening fields

Some certificates include additional panels beyond identity and purity.

The current GLP-3 RT information published by Void Research includes certificate examples with sterility, endotoxin, heavy-metal, and fentanyl-screen fields.

Each field has its own purpose.

A sterility result concerns microbial contamination under the applied test method.

An endotoxin test concerns bacterial endotoxin.

Heavy-metal testing evaluates specified elemental contaminants under the laboratory’s analytical method.

A fentanyl screen tests for the particular analyte or class described by that assay.

These fields should not be collapsed into one generic statement such as “safe.”

They are individual analytical results, each with its own scope, sensitivity, methodology, and limitations.

A certificate showing several passing fields does not establish properties that were never tested.

Laboratory verification is stronger than a screenshot alone

The presence of a PDF or image on a supplier website is useful, but a stronger documentation chain exists when the issuing laboratory provides a public verification mechanism.

Independent review by PeptideBenchmark reported that Void Research’s certificate archive contains reports associated with Freedom Diagnostics, ILS Laboratories, and Kovera Labs and that several published reports could be checked through the issuing laboratories’ verification routes.

The same review specifically noted that an ILS Laboratories GLP-3 RT certificate could be resolved through the laboratory’s verification system under the Void Research client name.

This does not mean every product or future lot is automatically verified.

It means that for a certificate with a usable laboratory verification path, a researcher can potentially move beyond the supplier-hosted copy and verify the document at the issuing laboratory.

That is a materially stronger documentation practice.

A useful COA verification sequence

A procurement reader can use a short verification sequence without turning the process into a complicated audit.

First, confirm the product identity.

Second, confirm the lot number.

Third, note the laboratory.

Fourth, check whether the certificate provides an accession number, COA number, search code, report number, QR code, verification token, or other identifier.

Fifth, use the issuing laboratory’s own verification route where one is available.

Sixth, compare the laboratory result with the supplier-displayed certificate.

Seventh, save the certificate with the procurement record if the material is being purchased for controlled laboratory work.

This creates a better audit trail than simply bookmarking a product page.

Why lot matching is essential

Peptide catalogs change quickly.

A product page may display an older certificate, a new certificate, multiple certificates, or different certificates by vial strength.

Even if the compound name is unchanged, a new batch may have different analytical results.

That means the question is not merely, “Does Void Research have a GLP-3 RT COA?”

The better question is, “Does the exact GLP-3 RT lot associated with the material I am evaluating have documentation, and what does that specific documentation show?”

This distinction becomes even more important when a supplier publishes historical certificates alongside current certificates.

Historical documents can be useful for assessing documentation practices over time, but they should not be substituted for the current lot.

Current documentation should be separated from historical evidence

Researchers often find old supplier reviews, cached pages, previous certificates, screenshots, social posts, forum discussions, and older price guides.

Those sources can provide context.

They should not override current lot documentation.

A historical COA can demonstrate that a supplier previously tested a particular compound or used a particular laboratory.

It cannot automatically establish the analytical status of material from a later batch.

The same principle applies to prices, stock status, shipping terms, and promotions.

Use historical content for context and current official documentation for current procurement decisions.

The earlier GLP-3 RT content cluster

Your existing publication inventory already contains several pages that form a useful research-content path around this subject.

The earlier Substack GLP-3 RT deep-product guide provides a product-specific foundation.

The more recent September 6 WordPress comparison focuses directly on GLP-3 RT versus GLP-2 TZ, while a corresponding Substack publication expands the cluster to GLP-3 RT, GLP-2 TZ, and CAGRI.

Those pages complement this article because this guide concentrates more heavily on procurement documentation and COA interpretation rather than simply repeating the receptor comparison.

For readers who want the mechanistic comparison first, the recent GLP-3 RT versus GLP-2 TZ publication is the most natural companion piece.

For readers who want the wider multi-pathway context, the GLP-3 RT, GLP-2 TZ, and CAGRI Substack article provides the broader transition from triple agonism and dual agonism to amylin-pathway research.

For readers who want the analytical side, the September 1 HPLC-purity-versus-identity material provides a logical next step.

What a COA cannot tell you

A COA should not be asked to answer questions outside its scope.

It does not establish that a compound is an approved medicine.

It does not establish that the material is suitable for self-administration.

It does not provide a dosing protocol.

It does not establish treatment efficacy.

It does not automatically establish pharmacological equivalence with pharmaceutical-grade investigational material used in a clinical trial.

It does not prove that every vial from a supplier is identical to the tested sample.

It does not replace a research institution’s own quality-control process.

It does not establish compliance with local laws, customs requirements, ethics rules, institutional protocols, or import restrictions.

Those are separate questions.

Why supplier material and clinical-trial material should not be conflated

Retatrutide, tirzepatide, and cagrilintide appear in scientific and clinical literature, but that does not mean every commercially labeled research product is equivalent to the investigational or pharmaceutical material used in those studies.

Scientific papers typically describe a defined compound produced and controlled within a formal research or development program.

A commercial research-material supplier may use the same underlying scientific name or a catalog abbreviation, but equivalence cannot be assumed merely from the name.

Analytical identity, purity, formulation, synthesis route, excipients, handling, storage, content, stability, impurities, and quality-control systems may differ.

For that reason, the responsible use of clinical literature in a supplier guide is to explain scientific context, not to transfer clinical outcomes to a supplier vial.

How to evaluate the research question before procurement

A laboratory should begin with the research question rather than the discount.

For GLP-3 RT, ask whether the project genuinely requires a triple GIP/GLP-1/glucagon receptor research compound.

For GLP-2 TZ, ask whether the experimental design is centered on dual GIP/GLP-1 receptor biology.

For CAGRI, determine whether the project is instead focused on amylin or calcitonin-family receptor mechanisms.

Next, determine what experimental system is being used.

A receptor-binding assay has different requirements from a cell-signaling assay.

A biochemical assay differs from an animal model.

A method-development project differs from a pharmacology project.

An analytical-reference workflow differs from a functional experiment.

Only after defining the research question and experimental system does procurement become meaningful.

Choosing documentation requirements before ordering

The laboratory should also decide what documentation it requires before a purchase is placed.

Examples might include:

a lot-specific COA;

identity data;

chromatographic purity data;

measured content;

specific contaminant testing;

a laboratory-verifiable certificate;

manufacturing or handling information;

storage information;

a current product specification;

and a documented chain between the purchased lot and the analytical report.

Not every experiment requires the same documentation.

The correct requirement is determined by the research protocol and the institution’s quality system, not by the number of badges displayed on a product page.

The BOOST30 offer in context

For qualified research procurement, Void Research’s promotional code is BOOST30, with the campaign wording up to 30% off.

The commercial offer should remain separate from the scientific evaluation.

A discount does not strengthen a COA.

A COA does not prove a clinical claim.

A receptor-mechanism paper does not confirm a supplier’s manufacturing quality.

A strong purchasing decision keeps those categories separate.

The practical order is:

define the research need;

identify the correct compound;

review the current product page;

match the lot;

inspect the COA;

verify the laboratory record where possible;

check current institutional and legal requirements;

then review the final commercial terms.

BOOST30 reminder: qualified research purchasers evaluating the Void Research catalog can consider the BOOST30 promotion for up to 30% off, but the research and documentation requirements should be established before the price incentive is considered.

International shipping and legal responsibility

Research-material shipping should not be interpreted as proof of legal importability.

A seller may be technically capable of sending a parcel to a destination while the destination jurisdiction imposes restrictions on importation, possession, laboratory use, customs classification, licensing, or other aspects of the transaction.

Researchers and procurement departments therefore need to check destination-country requirements independently.

Where international shipping is available, it should be understood as international shipping where permitted by law.

Depending on the destination, duties, taxes, VAT or GST, customs processing, importer-of-record requirements, delays, inspection, seizure risk, or other regulatory obligations may apply.

The recipient remains responsible for determining whether the proposed transaction and research activity comply with applicable law and institutional rules.

Questions researchers should ask about GLP-3 RT

Is GLP-3 RT the scientific name?

No. GLP-3 RT is a supplier catalog label used for retatrutide. Peer-reviewed scientific literature uses retatrutide.

Is GLP-3 RT the same research concept as GLP-2 TZ?

No. GLP-3 RT maps to retatrutide, which is studied as a triple GIP/GLP-1/glucagon receptor agonist. GLP-2 TZ maps to tirzepatide, a dual GIP/GLP-1 receptor agonist.

Is CAGRI another GLP agonist?

CAGRI refers to cagrilintide, which belongs to an amylin/calcitonin-family receptor research pathway rather than the same receptor architecture as retatrutide or tirzepatide.

Does 99%+ HPLC purity prove identity?

No. Purity and identity are separate analytical questions. A complete review should examine the methods and fields reported on the certificate.

Does a COA prove every vial from a supplier is identical?

No. A COA documents the tested sample or lot within the scope of the methods reported. Researchers should match the certificate to the relevant batch.

Is an eight-assay COA automatically better than every smaller panel?

Not necessarily. More testing fields can provide more information, but usefulness depends on which assays were performed, whether they are appropriate to the research requirement, the laboratory, the methods, the certificate’s verifiability, and whether the document actually matches the lot being purchased.

Can a supplier certificate replace internal laboratory QC?

That depends on the institution and protocol, but external supplier documentation should not automatically be treated as a replacement for an organization’s own required quality-control procedures.

Does a GLP-3 RT COA prove retatrutide’s biological effects?

No. Analytical testing and pharmacological evidence answer different questions.

Should clinical retatrutide studies be treated as proof for a supplier product?

No. Published studies provide scientific context for the molecule. They do not establish equivalence between investigational clinical material and a commercial research-material vial.

What is the most useful first check before ordering?

Confirm the scientific identity and research purpose, then inspect the current lot-specific documentation.

A documentation-first interpretation of the Void Research catalog

The strongest way to use a catalog such as Void Research is not to begin with a list of compounds and ask what each might “do.”

Instead, begin with the research objective and work backward.

If the hypothesis concerns triple-receptor signaling, literature on retatrutide may be relevant.

If it concerns dual GIP/GLP-1 signaling, tirzepatide literature may be relevant.

If it concerns amylin or calcitonin-family receptor signaling, cagrilintide literature may be relevant.

Then determine whether the proposed material has adequate documentation for the laboratory’s requirements.

That approach produces a much cleaner relationship between scientific literature, supplier documentation, experimental design, and procurement.

Final perspective

GLP-3 RT, GLP-2 TZ, and CAGRI may appear next to one another in a research catalog, but they represent distinct research pathways.

GLP-3 RT corresponds to retatrutide and a triple GIP/GLP-1/glucagon receptor research model.

GLP-2 TZ corresponds to tirzepatide and dual GIP/GLP-1 receptor agonism.

CAGRI corresponds to cagrilintide and amylin/calcitonin-family receptor research.

The correct comparison is therefore not which product has the most impressive label. It is which molecular identity and receptor architecture fit the experimental question.

Once that is established, the next priority is documentation.

Researchers should match the exact lot, identify the issuing laboratory, inspect purity and identity as separate fields, review measured content where available, examine any sterility, endotoxin, heavy-metal or other testing that is relevant to the protocol, and use laboratory verification systems where available.

A promotion is useful only after those scientific and procurement questions have been answered.

Qualified laboratory purchasers who have independently determined that Void Research material is appropriate for their lawful research can use BOOST30 for up to 30% off through the Void Research BOOST30 research catalog at https://voidresearch.shop/?ref=BOOST30.

Research-use-only reminder: these materials are for controlled laboratory and in-vitro research by qualified researchers only. They are not for human or veterinary use, consumption, administration, diagnosis, treatment, cure, prevention, clinical application, food, supplements, cosmetics, or personal experimentation.